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Purpose: In proliferative diabetic retinopathy (PDR) and other angiogenesis-associated diseases, increased levels of
cytokines, inflammatory cells, growth factors, and angiogenic factors are present. Vascular endothelial growth factor
(VEGF) appears to play a central role in mediating microvascular pathology in PDR. The purpose of the present study
was to search for the association between the –634 C/G polymorphism of the VEGF gene and PDR. Moreover, it was
hoped to determine whether serum and vitreous levels of VEGF are affected by genetic factors.
Methods: This cross-sectional case-control study enrolled 349 unrelated Slovene subjects (Caucasians) with type 2
diabetes mellitus. The case group consisted of 206 patients with an advanced form of PDR and for whom vitrectomy was
performed, and the control group had 143 patients who had no clinical signs of diabetic retinopathy but did have type 2
diabetes of more than 10 years duration. To analyze the genotype distribution we had to compare the genotype frequencies
in diabetics with PDR (cases, n=206) and diabetics without diabetic retinopathy (control group, n=143). Additionally, to
evaluate the effect of diabetes on the VEGF serum levels 2 groups, diabetics and non diabetics, were compared. First
group were diabetics (diabetics with PDR, n=104), and second group were 29 subjects without diabetes.
Results: The –634 C/G VEGF polymorphism was not associated with PDR. Mean serum and vitreous levels of VEGF
were statistically significantly higher in PDR in comparison to the control group. Moreover, significantly higher serum
and vitreous levels of VEGF were demonstrated in diabetics with the CC genotype compared to those with the other (CG
+ GG) genotypes.
Conclusions: VEGF is an important cytokine in PDR. Despite the effect of the –634 C/G VEGF polymorphism on serum
and vitreous levels of VEGF in PDR, it failed to contribute to the genetic susceptibility to PDR.
In  proliferative  diabetic  retinopathy  (PDR)  and  other
angiogenesis-associated  diseases,  increased  levels  of
cytokines, inflammatory cells, growth factors, and angiogenic
factors are present [1-5]. Vascular endothelial growth factor
(VEGF)  appears  to  play  a  central  role  in  mediating
microvascular  pathology  in  PDR.  VEGF  is  capable  of
inducing the earliest changes in diabetic retinopathy such as
leukostasis and blood-retinal barrier breakdown [6,7] as well
as macular edema and neovascularization in progression of
diabetic retinopathy [1]. In the vitreous of patients with PDR,
VEGF  levels  have  been  found  to  be  increased  [1,2,4,5].
Although diabetes duration and inadequate glycemic control
are important risk factors in the development of PDR, genetic
factors may play a significant role in the pathogenesis of PDR
[8,9]. There is considerable variation in VEGF expression
among  individuals,  with  several  different  polymorphisms
being  reported  [10].  The  VEGF  634  C/G  (rs2010963)
polymorphism in the 5′-untranslated region has been reported
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to  be  associated  with  variations  in  VEGF  serum
concentrations and with a susceptibility to disorders, such as
diabetic  retinopathy,  diabetic  nephropathy,  and
cardiovascular diseases [8,10-13].
To investigate the impact of genetic polymorphisms of
VEGF on PDR in a Slovenian population (Caucasians) with
type 2 diabetes, we searched for the association between the
-634 C/G VEGF polymorphism and PDR in subjects with type
2 diabetes. Moreover, the aim of the study was to determine
the serum and vitreous levels of VEGF of patients with PDR,
and whether serum and vitreous levels of VEGF are affected
by genetic factors.
METHODS
Patients: This cross-sectional case-control study enrolled 349
(age range 35 to 87 years; 152 men, 197 women) unrelated
Slovene subjects (Caucasians) with type 2 diabetes mellitus
who  had  a  defined  ophthalmologic  status.  Patients  were
classified as having type 2 diabetes according to the current
American Diabetes Association criteria for the diagnosis and
classification of diabetes [14]. Patients were recruited from
the Eye Clinic of the University Medical Centre Ljubljana
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1382between January 2002 and April 2007. Fundus examination
was performed by a senior ophthalmologist (M.G.P.) after
pupil dilatation (tropicamide and phenylephrine 2.5%) using
slit-lamp  biomicroscopy  with  non-contact  lens,  and  was
electronically documented with a 50°-angle fundus camera
(Topcon-TRC  40-IX;  Topcon,  Tokyo,  Japan).  Staging  of
diabetic retinopathy was determined according to the Early
Treatment  Diabetic  Retinopathy  Study  Research  Group
retinopathy severity scale [15].
The  study  group  consisted  of  206  patients  with  an
advanced form of PDR (new vessel formation as well as
fibrous proliferation with or without vitreous hemorrhage) in
whom  vitrectomy  was  indicated  and  performed  due  to
vitreous  hemorrhage,  macular  detachment,  or  macular
threatening detachment. The control group consisted of 143
patients  who  had  type  2  diabetes  of  more  than  10  years
duration but had no clinical signs of diabetic retinopathy.
In 68 out of 206 patients with PDR (71 eyes) 0.3 ml
vitreous fluid samples were obtained by vitreoretinal surgery.
The study excluded patients who had previous vitrectomy,
neovascularization of no diabetic etiology, recent vitreous
hemorrhage (less than two months), or a history of ocular
inflammation and photocoagulation in the preceding three
months.
Macular  edema  was  defined  as  being  clinically
significant  based  on  observations  rendered  by  the  Early
Treatment Diabetic Retinopathy Study [16]. PDR was found
to be active in 54 eyes and inactive in 17 eyes, according to
the  method  reported  by  Aiello  and  associates  [1].
Neovascularization was considered to be active if new vessels
were perfused, multibranching iridic, or preretinal capillaries;
it was considered to be inactive if previously documented
active proliferation had regressed fully or if only nonperfused
gliotic vessels or fibrosis were present [1]. The extent of
retinal laser photocoagulation was classified into three grades:
grade  1)  no  photocoagulation;  grade  2)  focal
photocoagulation; and grade 3) panretinal photocoagulation
(defined as extensive photocoagulation in all four quadrants
of the retina).
Sample collection: Fasting serum VEGF levels were analyzed
in 104 out 206 of patients with PDR and in 29 patients without
diabetes. Vitreous  fluid  samples  (0.3 ml) were obtained by
vitreoretinal surgery (from the midvitreous at the initial stage
of vitrectomy by aspiration into a 2 ml syringe attached to the
vitreous  counter  before  starting  intravitreal  infusion  of
balanced salt solution) from 71 eyes of 68 consecutive patients
with PDR, and from 17 eyes of 17 consecutive nondiabetic
patients  in  whom  vitrectomy  was  performed  because  of
idiopatic macular hole [17]. Vitreous was cut and aspirated
into a 2 ml syringe attached to the vitreous cutter before
starting intravitreal infusion of balanced salt solution.
Single  nucleotide  polymorphism  –634  C/G  gene
polymorphisms  and  diabetic  retinopathy:  The  –634  C/G
VEGF polymorphism was evaluated as described previously
[8]. Genotype determination: Genomic DNA was isolated
from peripheral blood lymphocytes by standard methods and
stored at -20 °C. Genotyping was carried out by polymerase
chain  reaction-restriction  fragment  length  polymorphism
(PCR-RFLP) analysis. In brief, each PCR reaction (20 μl)
contained 0.4 μl 10 mM dNTP (Gibco), 2 μl 10-X PCR buffer
(Gibco), 1.2 μl 25 mM MgCl2 (final concentration 1,5 mM),
1 μl 10 μM of each primer (5′-TTG CTT GCC ATT CCC CAC
TTG A-3′, 5′-CCG AAG CGA GAA CAG CCC AGA A-3′),
0.7 μl (500 ng) DNA, 12.5 μl H20, 1 μl 5% DMSO, 0,5 unit
of AmliTaq Gold DNA-polymerase (Applied Biosystems).
Cycling parameters were as follows: 3 min 94 °C for primary
denaturation, followed by 30 cycles of 1 minute 94 °C and 1
minute 59 °C, 1 minute 72 °C. After digestion for 16 hours at
65 °C by 1 unit of the restriction enzyme BsmFI, the restriction
products were electrophoresed on a 2.0% agarose gel and then
visualized using ethidium bromide staining. The -634G allele
result in the gain of a BsmFI site. Two investigators (B.P.,
D.P.), blinded for case or control status of the DNA sample,
performed the genotype classification.
VEGF serum concentration assay: For the determination of
fasting serum VEGF concentration (isoform VEGF 165), we
used a solid phase sandwich ELISA, which involved two
kinds of highly specific antibodies (hVEGF Assay Kit; IBL
Co.,  Ltd.,  Takasaki-shi,  Gunma,  Japan).  In  our  study  the
respective coefficient of variation (CV; %) were between 3
and 5.5 for interassay measurements, and between 2.6 and 5.3
for intraassay measurements.
The vitreous VEGF concentration was determined with
the cytometric bead array method (CBA; BD Biosciences, San
Diego,  CA).  The  samples  were  collected  in  sterile  tubes,
rapidly frozen and then stored at –80 C until analyzed. VEGF
concentrations were measured using CBA (BD Biosciences).
The VEGF capture beads were mixed with phycoerythrin –
conjugated detection antibodies. These capture beads were
incubated  with  recombinant  standards  or  test  samples
(vitreous)  to  form  sandwich  complexes.  Two-color  flow
cytometric analysis was performed using a FACSCalibur flow
cytometer  (BD  Biosciences).  Data  were  acquired  and
analyzed  using  Becton  Dickinson  Cytometric  Bead  Array
CBA software, and concentrations were determined from the
standard  curves,  plotting  recombinant  calibrator
concentration versus FL-2 mean fluorescence intensity.The
use of this method made it possible to detect two of the four
VEGF isoforms (VEGF 121 and VEGF 165).
Statistical analysis: We used a nonparametric Mann–Whitney
test and Kruskal–Wallis test for multiple group comparison or
the  Student  t-test  as  appropriate.  The  χ2  test  was  used  to
compare  discrete  variables  and  to  compare  genotype
distributions. In addition, all variables that showed significant
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1383differences by univariate methods (χ2 test, unpaired Student
t test) were analyzed together in a logistic regression analysis.
Statistical analysis was performed using the SPSS program
for Windows version 14 (SPSS Inc. Chicago, IL).
RESULTS
The characteristics of the cases and control subjects are listed
in Table 1. Cases had earlier onset of diabetes (45.2±12.1
years  vs.  53.3±12.1  years;  p<0.001)  and  longer  duration
(19.2±8.7 years vs. 16.5±6.6; p=0.009) of type 2 diabetes
compared to controls diabetics without diabetic retinopathy).
Additionally, they had higher incidence of insulin therapy
than  the  controls  (diabetics  without  diabetic  retinopathy).
There  were  no  significant  differences  in  hypertension,
smoking, total, high density lipoprotein (HDL) cholesterol,
and  low  density  lipoprotein  (LDL)  cholesterol,  and
triglyceride levels between the cases and controls.
Single  nucleotide  polymorphism  –634  C/G  VEGF
polymorphisms and PDF: The VEGF genotype distributions
in cases and controls (Table 2) were compatible with Hardy–
Weinberg expectations (–634 C/G: cases χ2=1.21, p=0.27; –
634 C/G: controls χ2=0.29, p=0.59). The –634 C/G VEGF
polymorphism was not associated with PDR in a group of
Caucasian subjects with type 2 diabetes (Table 2).
The variables that showed significant differences by χ2
test  and  unpaired  Student  t  test  (insulin  therapy,  diabetes
duration, age of diabetes onset) plus the VEGF polymorphism
were analyzed together in a logistic regression analysis. In the
logistic regression model (diabetes duration, age of diabetes
onset,  incidence  of  insulin  therapy,  and  the  VEGF
polymorphism) the CC genotype of the VEGF polymorphism
was not an independent risk factor for PDR (Table 3).
VEGF serum levels: Fasting serum VEGF levels in 104
PDR patients (55.3±25.1 ng/l) were significantly higher from
those  of  29  controls  without  diabetes  (13.8±10.2  ng/l;
p<0.001). To analyze the genotype distribution we had to
compare  the  genotype  frequencies  in  diabetics  with  PDR
(cases,  n=206)  and  diabetics  without  diabetic  retinopathy
(control group, n=143). However, to evaluate the effect of
diabetes on the VEGF serum levels 2 groups, diabetics and
non-diabetics,  were  compared.  First  group  were  diabetics
(diabetics  with  PDR,  n=104),  and  second  group  were  29
subjects without diabetes.
Moreover, we found significantly higher VEGF serum
levels in 24 PDR patients with the CC genotype (60.4±32.1
ng/l) compared to 80 PDR patients with the other (CG + GG)
genotypes (44.1±23.5 ng/l; p<0.01); 24 PDR patients with the
CC  genotype  did  not  differ  in  clinical  parameters  (age,
diabetes duration, age of diabetes onset, lipids, blood pressure,
incidence of insulin therapy, sex distribution, incidence of
smoking) from 80 PDR patients with the other genotypes (data
not shown).
TABLE 1. CHARACTERISTICS OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY (PDR; CASES) AND PATIENTS WITHOUT
DIABETIC RETINOPATHY (CONTROLS).
Characteristics PDR n (%) Controls n (%) p value
Number 206 143
Age (years) 65.0 ± 9.9 66.9 ± 11.5 0.2
Male sex (%) 95 (46.1) 57 (39.9) 0.2
Duration of diabetes (years) 19.2 ± 8.7 16.5 ± 6.6 0.009
Patients on insulin therapy (%) 154 (74.8) 66 (46.1) <0.001
Age of diabetes onset 45.2 ± 12.1 53.3 ± 12.1 <0.001
HbA1c (%) 8.1 ± 1.6 8.2 ± 1.6 0.3
Systolic blood pressure
(mmHg) 144 ± 24 145 ± 20 0.7
Diastolic blood pressure
(mmHg) 85 ± 12 84 ± 9 0.4
Body mass index (kg/m2) 28.1 ± 4.4 27.7 ± 4.4 0.9
History of hypertension (%) 159 (77.2) 100 (70) 0.1
Smokers (%) 25 (12.1) 15 (10.5) 0.9
Total cholesterol (mmol/l) 5.4 ± 1.2 5.5 ± 1.2 0.1
HDL cholesterol (mmol/l) 1.1 ± 0.4 1.2 ± 0.4 0.1
LDL cholesterol (mmol/l) 3.1 ± 1.0 3.2 ± 0.9 0.2
Triglycerides (mmol/l) 2.2 ± 1.3 2.6 ± 1.9 0.1
Cases had earlier onset of diabetes and longer duration of type 2 diabetes compared to controls (diabetics without diabetic
retinopathy).  Additionally, they had higher incidence of insulin therapy than the controls (diabetics without diabetic retinopathy).
Numbers are given as n (%). Abbreviations: HDL, high density lipoprotein, LDL, low density lipoprotein.
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1384We  failed,  however,  to  demonstrate  statistically
significant differences in fasting serum VEGF levels between
patients with macular edema (62.1±39.1 ng/l ) and patients
without macular edema (54.4±34.7 ng/l; p=0.4). Moreover,
we failed to demonstrate statistically significant differences
in fasting serum VEGF levels between patients with active
neovascularization  (56.3±41.8  ng/l  )  and  patients  without
active neovascularization (62.8±26.6 ng/l; p=0.5)
VEGF  vitreous  levels:  Vitreous  VEGF  levels  were
analyzed in 71 eyes of 68 patients with PDR, and from 17 eyes
of  17  patients  without  diabetes  in  whom  vitrectomy  was
performed due to idiopatic macular hole [17]. Mean vitreous
levels  of  VEGF  were  statistically  significantly  higher  in
diabetic  patients  with  PDR  (5283.51±5274.12  pg/ml  )in
comparison  to  the  control  group  (17.40±12.57  pg/ml;
p<0.001).
Vitreous VEGF levels were significantly higher in 12
eyes  from  12  patients  with  the  CC  genotype
(6061.52±5341.69  pg/ml  )  compared  to  59  eyes  from  56
subjects  with  the  other  (CG  +  GG)  genotypes
(3026.43±2842.17 pg/ml; p<0.01); 12 PDR eyes from 12 PDR
patients  with  the  CC  genotype  did  not  differ  in  clinical
parameters  (age,  diabetes  duration,  age  of  diabetes  onset,
lipids,  blood  pressure,  incidence  of  insulin  therapy,  sex
distribution,  incidence  of  smoking,  and  incidence  of
panretinal  photocoagulation)  from  59  PDR  eyes  from  56
patients with the other genotypes (data not shown).
Macular edema was present in 37 out of 71 eyes with
PDR.  Significantly  higher  vitreous  VEGF  levels  were
demonstrated  in  the  eyes  with  macular  edema
(6567.96±5780.66  pg/ml)  compared  to  34  eyes  without
macular edema (3885.73±4322.94 pg/ml; p=0.02).
Additionally,  we  wanted  to  compare  vitreous  VEGF
levels between active stage of PDR (54 eyes out of 71 in whom
vitrectomy was performed) and inactive stage of PDR (17 eyes
out of 71 in whom vitrectomy was performed). Statistically
significant differences between active (n=54) and inactive
stages (n=17) of PDR were demonstrated in vitreous levels of
VEGF (6666.25±5341.69 pg/ml versus 891.28±478.24 pg/ml;
p<0.001).
The extent of laser photocoagulation was related to the
vitreous level of VEGF. In the group of 13 eyes with no laser
photocoagulation (7541.46±6323.89 pg/ml), the VEGF level
was significantly higher compared to the group of 32 eyes with
incomplete photocoagulation (6631.64±5543.10 pg/ml) or the
TABLE 2. DISTRIBUTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR GENOTYPES/ALLELES IN PATIENTS WITH PROLIFERATIVE DIABETIC









Genotype CC 24 (11.6) 15 (10.5) 0. 71 1.1 (0.5–2.1)1
Genotype CG 103 (50.0) 67 (46.9)
Genotype GG 79 (38.4) 206 61 (42.6) 143
C allele 151 (36.7) 97 (33.9) 0. 52
G allele 261 (63.3) 189 (66.1)
Distribution of the –634 C/G vascular endothelial growth factor genotypes/alleles was compared between cases and controls.
The frequencies of genotypes and alleles are shown in percentage and as seen in the Table 3 there are no significant differences
between cases and controls in either the frequency of the CC genotype (CC versus CG plus GG: odds ratio 1.1, 95% confidence
interval 0.5–2.1; p value 0.7).  1p-value and odds ratio (CC versus CG plus GG),  2p value for allele frequency.
TABLE 3. LOGISTIC REGRESSION ANALYSIS FOR THE ASSOCIATION WITH PROLIFERATIVE DIABETIC RETINOPATHY AMONG
TYPE 2 DIABETIC PATIENTS.
Risk factor Odds ratio (95% CI)
* p
CC genotype
** 1.1 (0.7–1.6) 0.7
Patients on insulin therapy (%) 3.3 (1.9–5.7) < 0.001
Age of diabetes onset 1.06 (1.029–1.09) < 0.001
Duration of diabetes (years) 1.025 (0.983–1.068) 0.2
The asterisk indicates CI is confidence interval; the double asterisk shows the VEGF   -634 C/G polymorphism. In the logistic
regression model diabetes duration, age of diabetes onset, and incidence of insulin therapy were demonstrated to be an
independent risk factor for PDR, whereas the CC genotype of the VEGF polymorphism was not an independent risk factor for
PDR. The odd ratio for the CC genotype of the –634 C/G VEGF gene polymorphism is 1.1, 95% confidence interval is 0.7-1.6;
p=0.7.
Molecular Vision 2008; 14:1382-1387 <http://www.molvis.org/molvis/v14/a166> © 2008 Molecular Vision
1385group of 26 eyes with photocoagulation in all four quadrants
(2495.3±2743.56 pg/ml; p=0.001).
DISCUSSION
In our study we analyzed the VEGF –634 C/G polymorphism
as a potential genetic marker of PDR. The VEGF –634 C/G
polymorphism was not associated with PDR in a group of
Caucasians with type 2 diabetes. In accordance with our study,
Awata and coworkers [8] failed to demonstrate an association
between  the  CC  genotype  of  the  VEGF  –634  C/G
polymorphism and PDR, but they reported an association with
diabetic retinopathy. They compared 70 Japanese patients
with PDR (22.9% ) to 118 Japanese diabetics without diabetic
retinopathy  (10.3%),  and  they  failed  to  demonstrate  a
statistically significant difference (p=0.081) in the frequency
of  the  CC  genotype  [8].  Suganthalakshmi  and  coworkers
[12] compared 120 Indian patients with diabetic retinopathy
(17.5%) to 90 diabetics without diabetic retinopathy (30%),
and  they  failed  to  demonstrate  a  statistically  significant
difference  in  the  frequency  of  the  CC  genotype  (p=n.s.).
Moreover,  Awata  and  coworkers  [13]  have  recently
demonstrated  that  the  VEGF  C-634G  polymorphism  is  a
genetic risk factor for diabetic macular edema as well as
diabetic retinopathy.
Serum VEGF levels were found to be affected by genetic
factors (the VEGF –634 C/G polymorphism). We analyzed
fasting serum VEGF levels in 104 PDR patients and found
significantly higher VEGF serum levels in 24 patietns with
the CC genotype compared to 80 patients with the other (CG
+ GG) genotypes. The VEGF –634 C/G polymorphism is most
probably  a  functional  polymorphism,  since  significantly
higher VEGF serum levels have also been reported in healthy
subjects  with  the  CC  genotype  of  the  C(–634)G
polymorphism compared to those with the other genotypes
[8]. It was reported that a −634G>C substitution enhanced
VEGF  expression  at  both  transcriptional  and  translational
levels [18]. Additionally, fasting serum VEGF levels in 104
diabetics with PDR were significantly higher from those of 29
controls  without  diabetes.  Several  environmental  and
genetical factors (hypoxia, hyperglycemia, oxydative stress,
ischemia, VEGF gene polymorphism) influence serum VEGF
levels [8,19].
In our study, vitreous VEGF levels were found to be
affected by genetic factors (VEGF –634 C/G polymorphism)
and  by  local  factors  in  the  eyes  (extent  of  laser
photocoagulation). Vitreous VEGF levels were affected by
the VEGF –634 C/G polymorphism. Vitreous VEGF levels
were significantly higher in 12 PDR patients with the CC
genotype compared to 56 PDR patients with the other (CG +
GG) genotypes. In our study as well as in other studies it was
demonstrated that in PDR the extent of laser photocoagulation
significantly affects VEGF level [1,4].
Vitreous VEGF levels were statistically higher in PDR
eyes in comparison to the control group without diabetes,
which is in agreement with other studies [1,3-5]. In our study,
however, the levels of VEGF were higher than in other studies.
The reason for this discrepancy is probably due to different
methods of VEGF detection [20]. Moreover, vitreous VEGF
levels were significantly higher in 12 PDR patients with the
CC genotype compared to 56 PDR patients with the other (CG
+ GG) genotypes. We speculate that vitreous VEGF levels
were also found to be affected by genetic factors.
Significantly  higher  vitreous  VEGF  levels  were
demonstrated in the eyes with macular edema compared to the
eyes without macular edema. Our findings are in accordance
with  the  findings  of  Funatsu  and  coworkers  [4].  They
demonstrated  elevated  vitreous  VEGF  in  nonproliferative
diabetic macular edema [1,3-5]. Moreover, vitreous levels of
VEGF were elevated in active neovascularization in PDR that
is in agreement with other reports [1,21].
VEGF  is  an  important  mediator  in  pathogenesis  of
diabetic retinopathy [8,13,18,22]. In the present study we
demonstrated that the VEGF –634 C/G polymorphism affects
the vitreous and serum levels of VEGF in patients with PDR,
whereas  the  association,  on  the  other  hand,  has  not  been
demonstrated between the VEGF –634 C/G polymorphism
and PDR. We speculate that other factors are more important
than the VEGF –634 C/G polymorphism in the pathogenesis
of advanced form of PDR (our group of patients with PDR in
whom vitrectomy was performed).
In conclusion, VEGF is an important cytokine in PDR.
The serum and vitreous VEGF levels were statistically higher
in PDR eyes in comparison to the control group. Despite the
effect of the VEGF –634 C/G polymorphism on serum and
vitreous levels of VEGF in PDR, we found the VEGF –634
C/G  polymorphism  failed  to  contribute  to  the  genetic
susceptibility to PDR.
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